Search
Axitinib
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times...
Axitinib Drug Metabolism
smpdb.ca/view/SMP0130787MetabolicAxitinib passes through the liver and is then excreted from the body mainly through the kidney. … Axitinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis.
Drugs: AxitinibAxitinib Action Pathway
smpdb.ca/view/SMP0126901Drug actionAxitinib is an oral medication used to treat advanced renal cell carcinoma (kidney cancer) when one prior systemic therapy has not been effective. … Axitinib is recognized for its high potency compared to earlier VEGFR inhibitors and is available in oral formulations under the brand name Inlyta®.
PF-04856884
go.drugbank.com/drugs/DB17550Investigational[A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on Ma...
Advanced Renal Cell Carcinoma
go.drugbank.com/conditions/DBCOND0032596Drugs: Avelumab · Axitinib · Belzutifan · Cabozantinib · Hyaluronidase (human recombinant) · Lenvatinib +6 morePembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigationalPembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotyp...